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Apolipoprotein E (APOE) 34 genotype is associated with increased risk of Alzheimer’s disease and other
types of dementia. The level of cognitive dysfunction and its progression are also different in accordance
with different APOE genotypes among Alzheimer’s disease patients. Recently, essential tremor (ET) has
become regarded as a multisystem disorder and many studies have shown that ET patients have
cognitive deﬁcits and an increased risk of dementia. The role of APOE 34 in ET patients, however, remains
unidentiﬁed. In this study, we investigated the impact of APOE genotype on cognitive change in ET.
Among the 69 patients enrolled, 10 patients had more than one APOE 34 allele. The neuropsychological
data of the groups having APOE 34 and non- 34 were similar: the proportion of cognitive impairment was
not different between the 34 and non- 34 groups. The results of our study suggest that the possibility of
cognitive declines in ET is not inﬂuenced by the APOE 34 gene burden.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Essential tremor (ET) is one of the most prevalent movement
disorders. Its major symptoms are postural and kinetic tremors of
the distal part of the body. Recent surveys have reported that ET is
not a “pure” movement disorder, and has many aspects of non-
motor symptoms, such as cognitive dysfunctions, psycho-affective
symptoms and cerebellar dysfunctions1,2. A recent population-
based study in central Spain has shown that ET patients with
tremor onset after 65 years of age were more likely to have
dementia than the healthy control group3. Another prospective
population-based study in New York found that ET was associated
with both prevalence and risk of dementia4.
The apolipoprotein E (APOE) gene is the most prevalent gene for
Alzheimer’s disease (AD) and is likely to be involved in the path-
ogenesis of dementia5,6. APOE 34 also has a key role in disease
progression; carriers can experience faster and more severe
cognitive decline as well as having more severe Ab deposition, gray
matter atrophies, and cerebral blood ﬂow derangement in struc-
tural and functional neuroimaging7e9.terest.
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degenerative disease have been widely studied10. A recent
population-based, prospective study has found that APOE 34 is
associated with an increased risk for vascular dementia in an allele
dose-dependent fashion11. In addition, a high prevalence of APOE 34
was found in diffuse Lewy body disease10. However, no studies have
been conducted regarding the impact of APOE 34 on cognitive
change in patients with ET.
Herein, we aimed to evaluate the impact of APOE 34 haplotype
on the severity of cognitive dysfunctions in elderly patients with ET.
2. Methods
2.1. Participants
Sixty-nine consecutive newly-diagnosed ET patients were
enrolled in this study. The evaluation procedure involved a detailed
medical history, a physical and neurological examination, and
a neuropsychological assessment. The patients’ history of medical
and neurological problems was obtained with consent from the
patients and family members, or from other caregivers. All patients
were diagnosed with having core criteria for the diagnosis of ET12.
These criteria include the presence of bilateral action (postural or
kinetic) tremor of the hands and forearms in the absence of other
neurological signs (with the exception of the cogwheel
phenomena), or the presence of isolated head tremor with no signs
of dystonia. The secondary criteria (duration >3 years, positivecy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table1
Comparison of demographics between patients with APOE4 genotype and those
without.
Non-APOE 34
(n ¼ 59)
APOE 34
(n ¼ 10)
p
General characteristics
Age (yr) 66.1  9.2 69.0  6.4 0.343
Sex (male, %) 6 (10.2) 1 (10.0) 0.734
Education status (yr) 8.0  5.0 8.7  7.2 0.673
Disease duration (yr) 7.0  9.4 6.5  6.0 0.870
Vascular risk factors
Hypertension 11 (18.6) 3 (30.0) 0.326
Diabetes mellitus 3 (5.1) 0 (0.0) 0.620
Smoking 1 (1.7%) 0 (0.0) 0.855
Global tremor score 4.3  3.5 2.3  2.0 0.076
Values represent mean with standard deviation or numbers with percentages in
parentheses.
Analyses were performed with the independent-sample t-test for the continuous
variables, and the Pearson chi-squared test for the nominal variables.
Apolipoprotein E Unassociated with Cognition 51family history, and beneﬁcial response to alcohol) were also
applied12. Young-onset patients (50 years) were excluded from
this study because they were the least affected by cognitive change.
Patients were also excluded from the study if: (1) they had
neurological abnormalities related to systemic or other neurolog-
ical diseases, (2) they were taking medications reported to inﬂu-
ence cognition, such as anticholinergics or beta-blocking agents, or
(3) they were found to have an FMR gene mutation of fragile X
tremor and ataxia syndrome.
Tremor severity was determined by the global tremor score13.
This was obtained by summing the following nine items: right and
left arm tremor, as determined by history (two items); tremor at
rest of either the face, lips or chin (one item); tremor at rest of all
four limbs (four items); and action or postural tremor of both arms
(two items), as determined by examination.
This studywas approved by the local ethics committee, and each
patient provided written informed consent to participate.
2.2. Neuropsychological assessment
The patients’ general cognitive status and severity of dementia
were evaluated by the Korean version of the Mini-Mental State
Examination, Clinical Dementia Rating (CDR), and the sum of box of
CDR. Several cognitive domains were assessed by conducting
a detailed battery of neuropsychological tests14,15. The tests
included the digit span forward and backward test for attention and
workingmemory, the Korean version of the Boston Naming Test for
language, the Seoul verbal learning rest for verbal memory (i.e.
immediate recall, delayed recall, and recognition), the Rey-
Osterrieth Complex Figure Test (RCFT) for nonverbal, visuospatial
memory (immediate recall, delayed recall, and recognition), the
RCFT copy for visuospatial function, the Color-Word Stroop Test
(word reading and color reading), the Controlled Oral Word Asso-
ciation test (semantic: animals, grocery items; and phonemic:
Korean letters) for word ﬂuency16e20. Frontal motor functions were
assessed by motor impersistence, contrasting program, goeno go
test, ﬁsteedgeepalm, alternating hand movement, alternating
square and triangle, and Luria loop tests. The resulting scores of
these tests were classiﬁed as abnormal if they were below the 16th
percentile of age-, sex-, and education-matched normal subjects14.
Dementia was diagnosed according to the criteria in the Diag-
nostic and Statistical Manual of Mental Disorders, 4th edition21. In
line with the concept of mild cognitive impairment suggested by
Petersen and colleagues22, the diagnosis of mild cognitive impair-
ment (MCI) in patients with ET was made if at least one out of ﬁve
cognitive domains were found to be abnormal.
2.3. Determination of APOE genotype
The detailed method used for APOE genotyping is described
elsewhere. In brief, genomic DNA was extracted from whole-blood
samples and ampliﬁed with polymerase chain reaction, as
described by Wenham et al23.
2.4. Data analysis
The statistical analyses were performed using SPSS software
version 15.0 (SPSS, Chicago, IL, USA). Comparisons of the demo-
graphics were done using the independent-sample t test for the
continuous variables, and Pearson chi-squared test for the nominal
variables. The general and speciﬁc neurocognitive functions were
compared between APOE 34 and non- 34 groups using the analysis
of covariance, including age and education status as confounding
covariates. Comparisons of APOE 34 allelic prevalence among
normal cognition, MCI and dementia were performed using chi-squared analysis. The level of statistical signiﬁcance was set at
p < 0.05.3. Results
Among the 69 patients (including seven males and 62 females;
mean age  standard deviation: 66.5  8.9 years), 31, 32 and six
patients were assigned to the normal cognition, MCI, and dementia
groups, respectively. The participants’ mean disease duration was
7.0  9.0 years and the mean duration of education was 8.1  5.4
years. Ten patients had more than one APOE 34 genotype (APOE 32/
34: 3, 3 / 34: 6 and 34/ 34: 1, respectively).
The data from the groups having APOE 34 and non- 34 were
similar for the age at examination and the age at onset, gender
distribution, length of education, and presence of cardiovascular
risk factors. The tremor severity, as measured by the global tremor
score, was not statistically different between the two groups
(Table 1).
There were no differences in general cognitive functions
between APOE 34 and non- 34 groups. The data also demonstrated
that there were no signiﬁcant differences in all cognitive domains.
In addition, the proportion of cognitive impairment was not
statistically different between the 34 and non- 34 groups (Table 2).4. Discussion
The APOE gene is recognized as the most important and
powerful genetic risk factor for AD. The APOE 34 genotype is likely
to increase the risk of developing AD and lead to malignant clinical
courses for both AD and MCI. APOE 34 inﬂuences AD pathology,
interacting with the metabolism of amyloid precursor protein and
with the accumulation of beta amyloid peptide, thus enhancing the
hyperphosphorylation of tau protein and the formation of neuro-
ﬁbrillary tangles5,6.
There were no data, however, about the inﬂuence of the APOE 34
gene burden on cognitive decline in patients with ET. In this study,
we investigated the effect of the APOE genotype on the cognitive
functions of ET, and found no signiﬁcant difference in the distri-
bution of cognitive diagnosis between APOE 34 and non- 34 groups.
In addition, the 34 allele did not inﬂuence any of the cognitive
subdomains. This result suggests that cognitive declines in ET are
not inﬂuenced by APOE 34 allele burden, and thus APOE 34 is
probably not associated with poor cognitive outcome in ET.
Although many studies have shown that ET patients have
cognitive deﬁcits and an increased risk of dementia2e4, the
Table 2
Neuropsychological test results for the non-APOE4 and APOE4 groups.
Non-APOE ε4 APOE ε4 p
General cognitive functions
K-MMSE score 26.1  3.6 26.9  2.4 0.483
CDR 0.4  0.3 0.5  0.2 0.885
Sum of box of CDR 1.5  1.3 1.6  1.0 0.712
Attention and working memory tests
Digit span forward 5.3  1.6 4.6  1.1 0.068
Digit span backward 3.5  1.4 3.4  0.8 0.862
Language functions
Korean version of the Boston
Naming Test
26.0  19.2 26.3  15.9 0.888
Calculation 9.7  3.0 9.7  2.5 0.808
Visuospatial functions
RCFT copy 28.9  9.4 29.7  6.5 0.808
Verbal memory functions (Seoul verbal learning test)
Immediate recall 19.8  5.7 18.4  4.0 0.478
Delayed recall 6.3  3.0 6.4  2.1 0.836
Visuospatial memory functions
RCFT, immediate recall 11.5  6.8 10.4  4.7 0.663
RCFT, delayed recall 11.4  7.3 10.1  5.8 0.604
Abnormal frontal motor functions* 9 (15.3%) 1 (10.0%) 0.663
COWAT
Animal 13.6  4.1 13.1  3.1 0.643
Supermarket 17.1  10.0 14.3  4.1 0.485
Phonemic (three Korean letters) 17.6  13.4 14.4  11.7 0.174
Stroop tests
Word 97.2  32.6 105.2  15.3 0.361
Color 73.9  28.7 74.7  18.1 0.825
Cognitive diagnosis*
Normal cognition 27 (45.8) 4 (40.0) 0.942
Mild cognitive impairment 27 (45.8) 5 (50.0)
Dementia 5 (8.4) 1 (10.0)
Values represent mean with standard deviation or numbers with percentages in
parentheses.
Analyses were performed by analyses of covariance, controlling for age and duration
of education.
Abnormal frontal motor function represents numbers of patients who have more
than two abnormalities of the frontal motor function tests.
CDR ¼ Clinical Dementia Rating; COWAT ¼ Controlled Oral Word Association test;
K-MMSE ¼ Korean version of Mini Mental Status Examination; RCFT ¼ Rey-Oster-
rieth Complex Figure test.
* Analysis was performed using the Pearson chi-squared test.
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Postmortem studies in ET brain have demonstrated degenerative
changes in the cerebellum or Lewy body in the brainstem24. In
addition, multiple lines of evidence suggest that the circuitry
involved includes the frontalesubcorticalecerebellar pathways,
which play a role in both cognitive and affective processes in
patients with ET25e27. There is, however, a lack of evidence for the
substrates causing clinical and pathological changes because the
Lewy bodies are conﬁned within the locus ceruleus, and the
inﬂuence of cerebellar degeneration on cognition is also unclear24.
Moreover, these incidental neuropathological ﬁndings have been
found in more than 10% of asymptomatic, elderly people28. Recent
investigation on themicrotubule-associated protein tau (MAPT) gene
in ET patients showed the increasing frequency of MAPT H1
haplotype was associated with an increasing risk of ET29. We can
therefore speculate that the role of APOE in ET may be mechanis-
tically distinct from that in other neurological disorders associated
with APOE 34.
The limitations of the present study include the fact that the
number of patients enrolled was small and their diagnosis had not
been pathologically or radiologically conﬁrmed. To identify theprecise role of the APOE gene, immunohistochemical staining or
amyloid scan is more helpful. Another major weakness of this study
is the absence of imaging characteristics that might identify
patients with possible vascular or mixed dementia. Finally, the
cognitive deﬁcits in patients with ET may be the result of the
misclassiﬁcation of some patients with Parkinson’s disease as
having ET. In our cases, the duration of disease averaged 7.0 years;
therefore, it is unlikely that any of these patients were in the early
stages of Parkinson’s disease.
In summary, this study suggests that APOE 34 allele burden does
not inﬂuence the cognitive dysfunction of ET and the possibility of
cognitive decline in ET is associated with other genetic/environ-
mental factors. The case-control comparisons would be needed to
identify the inﬂuencing of the APOE genotype in ET on the risk of
cognitive dysfunction.Acknowledgments
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